* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Iquix Drug Monograph
Survey
Document related concepts
Neuropsychopharmacology wikipedia , lookup
Discovery and development of integrase inhibitors wikipedia , lookup
Discovery and development of cephalosporins wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Compounding wikipedia , lookup
Neuropharmacology wikipedia , lookup
Pharmacognosy wikipedia , lookup
List of comic book drugs wikipedia , lookup
Levofloxacin wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Drug interaction wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Theralizumab wikipedia , lookup
Prescription costs wikipedia , lookup
Drug design wikipedia , lookup
Transcript
Preferred Drug List NEW DRUG REVIEW Proprietary Name: Iquix® Common Name: Levofloxacin PDL Category: Op. Quinolones 4th Generation Comparable Products Vigamox® Zymar® Preferred Drug List/ Recommended Drug List Status Preferred Non-Preferred Summary Indications and Usage: Treatment of bacterial corneal ulcer with activity against a broad spectrum of Gram-positive and Gram-negative ocular pathogens.1 Mechanism of Action: Inhibits bacterial topoisomerase IV and DNA gyrase, enzymes required for DNA replication, transcription, repair, and recombination.1 Dosage Forms: Solution, ophthalmic: 1.5% Recommended Dosage: 1 to 2 drops in the affected eye every 30 minutes to 2 hours while awake and 4 and 6 hours after bedtime for the first 3 days, then 1 to 2 drops every 1 to 4 hours while awake for the rest of the treatment duration.1 Common Adverse Drug Reactions: Headache, taste disturbance.1 Contraindications: Patients with a history of hypersensitivity to levofloxacin, to other quinolones, or to any of the components in this medication.1 Manufacturer: Santen Analysis: Iquix® is a fluoroquinolone ophthalmic solution indicated for the treatment of bacterial corneal ulcer with activity against a broad spectrum of Gram-positive and Gram-negative ocular pathogens. Iquix® binds stronger to DNA gyrase, while Vigamox® and Zymar® bind with a high affinity to both topoisomerase IV and DNA gyrase. In two randomized, double masked, multicenter controlled clinical trials comparing Iquix® and ofloxacin ophthalmic solutions, mean clinical cure rates were approximately similar at 80% and 84%, respectively. An advantage of Iquix® is its preservative-free status, however Vigamox® also is preservative free.1 Preferred alternatives appear on the Preferred Drug List which are more cost effective. Therefore, it is recommended that Iquix® be added to the Preferred Drug List as a non-preferred drug. Preferred Drug Non-Preferred Drug Preferred Drug with Conditions 1. Iquix® [package insert]. Tampere, Finland: Santen; 2007. IME Recommendation: Prepared By: Iowa Medicaid Enterprise Recommended Drug Non-Recommended Drug Date: 10/14/2008 PA Criteria Proposal z 2 © 2002 Heritage Information Systems, Inc. All Rights Reserved.